// App-Quantinova.ai

DMT52 : Inverse Relationship between Plasma Neurofilament Light Chain Concentration and Symbol Digit Modalities Test Scores in the Sunbeam Trial of Ozanimod in RMS

Researchers

Presenter

  • Sarah Harris

Principal Investigators

  • Giancarlo Comi

  • Bruce A.C. Cree

  • Douglas L Arnold

  • Lawrence Steinman

  • James K. Sheffield

  • Harry Southworth

  • Rachel Maddux

  • Ludwig Kappos

  • Jeffrey A Cohen

Medical Centers

  • Montreal Neurological Institute, McGill University and NeuroRx Research Inc., Montreal, QC, CANADA

  • Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA

  • Mellen Center, Cleveland Clinic, Cleveland, OH

  • Vita-Salute San Raffaele University and Casa di Cura del Policlinico

  • Research Center for Clinical Neuroimmunology and Neuroscience Basel (RCNB), Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland

  • 6Beckman Center for Molecular Medicine, Stanford University Medical Center Stanford CA United States

  • Bristol-Myers Sqiubb, Princeton, NJ

Locations

  • United Kingdom

  • United States

  • Italy

  • Canada

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Ozanimod

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved